Lilly scores FDA okay for Cyramza in liver cancer

Last year sales rose 8% to around $820m making it Lilly’s second-largest cancer drug after $2bn lung cancer blockbuster Alimta (pemetrexed), but it has come under pressure as a

Trulicity’s ascent lifts Lilly

The company also recently gained FDA approval for Alimta in combination with Keytruda and platinum chemotherapy for the first-line treatment of patients with metastatic NSCLC with no EGFR or ALK

EMA says Lilly’s Lartruvo should not be prescribed

The product was viewed as an important element in Lilly’s efforts to prop up its oncology franchise after the loss of patent protection for blockbuster Alimta (pemetrexed) in some markets,

Lilly adds to pharma M&A run with $8bn Loxo buy-out

Lilly does have presence in the lung cancer field with Alimta, and as this drug is nearing patent expiry, Loxo should provide the firm with opportunities to seize a share of

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]